导读门脉性肺动脉高压（portopulmonary hypertension，PoPH）是门静脉高压的一种常见并发症，目前被归为肺动脉高压（pulmonary arterial hypertension，PAH）的一个亚型。PoPH的发病机制尚不明确，可能与血流高动力循环、血管活性介质失调、遗传变异等因素相关。

导读门脉性肺动脉高压（portopulmonary hypertension，PoPH）是门静脉高压的一种常见并发症，目前被归为肺动脉高压（pulmonary arterial hypertension，PAH）的 ...

导读门脉性肺动脉高压（portopulmonary hypertension，PoPH）是门静脉高压的一种常见并发症，目前被归为肺动脉高压（pulmonary arterial hypertension，PAH）的 ...

Charles D. Burger, MD: Portopulmonary hypertension is a subgroup of Group 1 pulmonary arterial hypertension [PAH], and it occurs in the setting of hepatic cirrhosis or end-stage liver disease.

Portopulmonary hypertension is a relatively common complication of end-stage liver disease. Mild disease is not a contraindication to liver transplantation, but moderate disease is associated with ...

Experts review the challenging nature of portopulmonary hypertension and the appropriate treatment regimens used in this setting. Transcript. Hilary M. DuBrock, MD: Patients with portopulmonary ...

Portopulmonary hypertension (PoPH) is a form of pulmonary arterial hypertension (PAH). PoPH occurs in approximately 15% of patients with PAH, and is reportedly found in 2-6% of patients with ...

Intrapulmonary vascular dilatations occurred more commonly in patients with portopulmonary hypertension and were associated with decreased overall survival, according to study data published in ...

Recent data suggest that the endothelin receptor antagonist macitentan can be used to target the endothelin pathway in patients with portopulmonary hypertension. SAN ANTONIO — In patients with ...

The findings "Provide important clinical evidence to help inform treatment decisions and fill an unmet need that should benefit patients living with PoPH.” Johnson & Johnson’s Opsumit (macitentan) has ...

Actelion has unveiled new data showing that the first ever randomised, controlled clinical trial investigating Opsumit as potential treatment for portopulmonary hypertension (PoPH) hit its primary ...